Jamie B Oughton
Overview
Explore the profile of Jamie B Oughton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McNamara M, Swain J, Craig Z, Sharma R, Faluyi O, Wadsley J, et al.
EClinicalMedicine
. 2023 Jun;
60:102015.
PMID: 37287870
Background: The prognosis for patients with poorly-differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) is poor. A recognised first-line (1L) treatment for advanced disease is etoposide/platinum-based chemotherapy with no standard second-line (2L) treatment....
2.
Ravichandran S, Hall A, Jenner M, Garg M, Kishore B, Lachmann H, et al.
Amyloid
. 2023 May;
30(3):290-296.
PMID: 37216268
Introduction: Proteasome inhibitors are the backbone of AL amyloidosis treatment - bortezomib being most widely used. Carfilzomib is a proteasome inhibitor licenced to treat multiple myeloma; autonomic and peripheral neuropathy...
3.
Walker K, Hinsley S, Phillip R, Oughton J, Murden G, Chalmers A, et al.
JCO Precis Oncol
. 2022 Nov;
6:e2200133.
PMID: 36446040
Purpose: CONCORDE is the first phase I drug-radiotherapy (RT) combination platform in non-small-cell lung cancer, designed to assess multiple different DNA damage response inhibitors in combination with radical thoracic RT....
4.
Munir T, Emmerson J, Hockaday A, Oughton J, Howard D, Phillips D, et al.
Br J Haematol
. 2022 Aug;
199(5):707-719.
PMID: 36017875
The GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In chronic lymphocytic leukaemia (CLL) (GALACTIC) was a seamless phase II/III trial designed to test whether consolidation with obinutuzumab is safe and...
5.
Cragg W, McMahon K, Oughton J, Sigsworth R, Taylor C, Napp V
Trials
. 2021 Nov;
22(1):862.
PMID: 34844638
No abstract available.
6.
Cragg W, McMahon K, Oughton J, Sigsworth R, Taylor C, Napp V
Trials
. 2021 Oct;
22(1):736.
PMID: 34689802
Background: Eligibility criteria are a fundamental element of clinical trial design, defining who can and who should not participate in a trial. Problems with the design or application of criteria...
7.
Allsup D, Howard D, Emmerson J, Hockaday A, Rawstron A, Oughton J, et al.
Br J Haematol
. 2021 May;
194(3):646-650.
PMID: 34028800
No abstract available.
8.
Howard D, Hockaday A, Brown J, Gregory W, Todd S, Munir T, et al.
Trials
. 2021 Jan;
22(1):38.
PMID: 33419469
Background: The FLAIR trial in chronic lymphocytic leukaemia has a randomised, controlled, open-label, confirmatory, platform design. FLAIR was successfully amended to include an emerging promising experimental therapy to expedite its...
9.
Walls G, Oughton J, Chalmers A, Brown S, Collinson F, Forster M, et al.
Clin Transl Radiat Oncol
. 2020 Oct;
25:61-66.
PMID: 33072895
Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to...
10.
Collett L, Howard D, Munir T, McParland L, Oughton J, Rawstron A, et al.
Trials
. 2017 Aug;
18(1):387.
PMID: 28830517
Background: Treatment of chronic lymphocytic leukaemia (CLL) has seen a substantial improvement over the last few years. Combination immunochemotherapy, such as fludarabine, cyclophosphamide and rituximab (FCR), is now standard first-line...